Patents by Inventor Samantha Perino

Samantha Perino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HSP90-BINDING CONJUGATES AND COMBINATION THERAPIES THEREOF
    Publication number: 20220257777
    Abstract: The disclosure generally relates to a method of treating cancer comprising administering HSP90-binding conjugates or administering two distinct therapeutic agents as a combination therapy. Components of the combination therapy and methods of using the combination therapy are provided.
    Type: Application
    Filed: June 24, 2020
    Publication date: August 18, 2022
    Inventors: Jeffrey BLOSS, Samantha PERINO, James M. QUINN, Kerry WHALEN, Richard WOOSTER, Kristina KRIKSCIUKAITE, Laura E. MEI, Mark T. BILODEAU
  • SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
    Publication number: 20220096646
    Abstract: Conjugates of an active agent such as DM1 attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.
    Type: Application
    Filed: September 30, 2021
    Publication date: March 31, 2022
    Inventors: Richard Wooster, Kerry Whalen, Patrick Rosaire Bazinet, Mark T. Bilodeau, Sudhakar Kadiyala, Samantha Perino, Beata Sweryda-Krawiec, Rajesh R. Shinde
  • SSTR-targeted conjugates and particles and formulations thereof
    Patent number: 11160871
    Abstract: Conjugates of an active agent such as DM1 attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: November 2, 2021
    Assignee: TARVEDA THERAPEUTICS, INC.
    Inventors: Richard Wooster, Kerry Whalen, Patrick Rosaire Bazinet, Mark T. Bilodeau, Sudhakar Kadiyala, Samantha Perino, Beata Sweryda-Krawiec, Rajesh R. Shinde
  • COMBINATION THERAPY
    Publication number: 20210186978
    Abstract: The invention generally relates to a combination therapy for treating cancer comprising administering at least two distinct therapeutic agents. Components of the combination therapy and methods of using the combination therapy are provided.
    Type: Application
    Filed: May 31, 2019
    Publication date: June 24, 2021
    Inventors: Kerry WHALEN, Samantha PERINO, Richard WOOSTER, Sudhakar KADIYALA, James M. QUINN
  • ANTI-NOTCH3 ANTIBODIES
    Publication number: 20210171627
    Abstract: Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of Notch3.
    Type: Application
    Filed: August 13, 2020
    Publication date: June 10, 2021
    Inventors: Heidi Okamura, Sandra Abbott, Alisa C. Bell, Kelly Kreuter, Ronan O'Hagan, Samantha Perino, Hamid Tissire, William M. Winston, Jr., Jeno Gyuris
  • HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
    Publication number: 20210000966
    Abstract: Conjugates of an active agent attached to a targeting moiety, such as an HSP90 binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.
    Type: Application
    Filed: December 14, 2018
    Publication date: January 7, 2021
    Inventors: Tyler Cipriani, Benoît Moreau, Mark T. Bilodeau, James M. Quinn, Richard Wooster, Amanda L. Cirello, Samantha Perino, Kerry Whalen, Sudhakar Kadiyala, Brian H. White
  • Anti-NOTCH3 antibodies
    Patent number: 10745476
    Abstract: Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of Notch3.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: August 18, 2020
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Heidi Okamura, Sandra Abbott, Alisa C. Bell, Kelly Kreuter, Ronan O'Hagan, Samantha Perino, Hamid Tissire, William M. Winston, Jr., Jeno Gyuris
  • COMBINATION THERAPIES COMPRISING TARGETED THERAPEUTICS
    Publication number: 20200230247
    Abstract: The invention generally relates to a combination therapy for treating cancer comprising administering at least two distinct therapeutic agents. Components of the combination therapy and methods of using the combination therapy are provided.
    Type: Application
    Filed: June 19, 2018
    Publication date: July 23, 2020
    Inventors: Richard Wooster, Kerry Whalen, Mary Simcox, Leila Alland, Mark T. Bilodeau, Sudhakar Kadiyala, Samantha Perino
  • ANTI-NOTCH3 ANTIBODIES
    Publication number: 20180230213
    Abstract: Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of Notch3.
    Type: Application
    Filed: January 8, 2018
    Publication date: August 16, 2018
    Inventors: Heidi Okamura, Sandra Abbott, Alisa C. Bell, Kelly Kreuter, Ronan O'Hagan, Samantha Perino, Hamid Tissire, William M. Winston, JR., Jeno Gyuris
  • SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
    Publication number: 20180221499
    Abstract: Conjugates of an active agent such as DM1 attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.
    Type: Application
    Filed: October 28, 2016
    Publication date: August 9, 2018
    Inventors: Richard Wooster, Kerry Whalen, Patrick Rosaire Bazinet, Mark T. Bilodeau, Sudhakar Kadiyala, Samantha Perino, Beata Sweryda-Krawiec, Rajesh R. Shinde
  • Anti-Notch3 antibodies
    Patent number: 9879083
    Abstract: Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of Notch3.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: January 30, 2018
    Assignee: AVEO Pharmaceuticals, Inc.
    Inventors: Heidi Okamura, Sandra Abbott, Alisa C. Bell, Kelly Kreuter, Ronan O'Hagan, Samantha Perino, Hamid Tissire, William M. Winston, Jr., Jeno Gyuris
  • ANTI-NOTCH3 ANTIBODIES
    Publication number: 20160185852
    Abstract: Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of Notch3.
    Type: Application
    Filed: December 19, 2013
    Publication date: June 30, 2016
    Inventors: Heidi Okamura, Sandra Abbott, Alisa C. Bell, Kelly Kreuter, Ronan O'Hagan, Samantha Perino, Hamid Tissire, William M. Winston, JR., Jeno Gyuris